Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Laura Nguyen

Family Medicine Champlin, MN Medical Doctor

NPI 1881955193 CMS profile 1936140

12142 Business Park Blvd N, Ste 1109, Champlin, MN 55316

Open in the dashboard

General payments

$3,370

229 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Nguyen of Champlin, MN is reported in the CMS Open Payments database as having received $3,370 across 229 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18 1
2023 General $252 13
2022 General $873 57
2021 General $1,096 75
2020 General $479 33
2019 General $652 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Nguyen
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Laura Nguyen were reported at $18. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Laura Nguyen Family Medicine median Middle half National median
2019 $652 $150 $41–$543 $163
2020 $479 $120 $32–$415 $114
2021 $1,096 $137 $35–$551 $132
2022 $873 $137 $37–$512 $149
2023 $252 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $18 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $400 27 payments
  2. Abbott Laboratories $344 18 payments
  3. Novo Nordisk Inc $344 25 payments
  4. Lilly USA, LLC $315 28 payments
  5. AstraZeneca Pharmaceuticals LP $314 21 payments
  6. Merck Sharp & Dohme Corporation $270 19 payments
  7. GlaxoSmithKline, LLC. $204 13 payments
  8. Amarin Pharma Inc. $200 12 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $137 12 payments
  10. Pfizer Inc. $114 8 payments
  11. Other $727 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,363 228 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $267 19 payments
  2. STEGLATRO $234 16 payments
  3. FARXIGA $213 14 payments
  4. JANUVIA $194 14 payments
  5. BELSOMRA $191 13 payments
  6. STEGLUJAN $185 13 payments
  7. FreeStyle Libre 3 $180 9 payments
  8. JARDIANCE $176 17 payments
  9. EMGALITY $168 12 payments
  10. Ozempic $166 13 payments
  11. Other $2,963 203 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

399

Median for Family Practice: 1,826

Drug cost

$5,905

Median for Family Practice: $120,094

Branded share of claims

14%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Atorvastatin Calcium Generic 77 $1,094
Omeprazole Generic 26 $661
Amlodipine Besylate Generic 52 $572
Losartan Potassium Generic 38 $546
Lisinopril Generic 35 $441
Bupropion Xl Bupropion Hcl Brand 13 $431
Famotidine Generic 23 $342
Metformin Hcl Er Metformin Hcl Brand 32 $321
Trazodone Hcl Generic 12 $271
Levothyroxine Sodium Generic 16 $270

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$8,887

Medicare's payments for the services billed

Medicare patients

36

Average age 70

Services billed

151

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Depression 42%
Arthritis 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

229 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record